Cargando…
Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib
We aimed to explore symptom severity and adherence to therapy for patients with myelofibrosis treated with ruxolitinib in Bulgaria. It is a prospective, non-interventional study performed at the specialized hospital for active treatment of hematological diseases in Sofia during 2022–2023. Date of di...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383504/ https://www.ncbi.nlm.nih.gov/pubmed/37513888 http://dx.doi.org/10.3390/ph16070976 |
_version_ | 1785080926727831552 |
---|---|
author | Stoeva, Vera Petrova, Guenka Mitov, Konstantin Tachkov, Konstantin |
author_facet | Stoeva, Vera Petrova, Guenka Mitov, Konstantin Tachkov, Konstantin |
author_sort | Stoeva, Vera |
collection | PubMed |
description | We aimed to explore symptom severity and adherence to therapy for patients with myelofibrosis treated with ruxolitinib in Bulgaria. It is a prospective, non-interventional study performed at the specialized hospital for active treatment of hematological diseases in Sofia during 2022–2023. Date of diagnosis, demographic characteristics, clinical indicators, ruxolitinib dose, and other data points were collected. Clinical indicators were assessed at baseline, in the middle, and at the end of observation. Severity of symptoms was measured with MPN-SAF TSS and adherence to therapy with the Morisky 4 questionnaire six times during the observation. The mean age of diagnosis was 58.5 years, with the average duration of disease of 3 years. Patients’ laboratory results were within physiological ranges, with spleen size experiencing a constant decrease. The average value for the severity of the symptoms per MPN-SAF TSS results decreased significantly, indicating better disease control. The average adherence to therapy did not change and remained high at around 9 points, except for one patient. In conclusion the treatment of myelofibrosis patients with ruxolitinib decreased symptom severity and spleen size. Patients were adherent to the therapy over the observed period, but as treatment duration increases, the risk of adherence decreases. |
format | Online Article Text |
id | pubmed-10383504 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103835042023-07-30 Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib Stoeva, Vera Petrova, Guenka Mitov, Konstantin Tachkov, Konstantin Pharmaceuticals (Basel) Article We aimed to explore symptom severity and adherence to therapy for patients with myelofibrosis treated with ruxolitinib in Bulgaria. It is a prospective, non-interventional study performed at the specialized hospital for active treatment of hematological diseases in Sofia during 2022–2023. Date of diagnosis, demographic characteristics, clinical indicators, ruxolitinib dose, and other data points were collected. Clinical indicators were assessed at baseline, in the middle, and at the end of observation. Severity of symptoms was measured with MPN-SAF TSS and adherence to therapy with the Morisky 4 questionnaire six times during the observation. The mean age of diagnosis was 58.5 years, with the average duration of disease of 3 years. Patients’ laboratory results were within physiological ranges, with spleen size experiencing a constant decrease. The average value for the severity of the symptoms per MPN-SAF TSS results decreased significantly, indicating better disease control. The average adherence to therapy did not change and remained high at around 9 points, except for one patient. In conclusion the treatment of myelofibrosis patients with ruxolitinib decreased symptom severity and spleen size. Patients were adherent to the therapy over the observed period, but as treatment duration increases, the risk of adherence decreases. MDPI 2023-07-07 /pmc/articles/PMC10383504/ /pubmed/37513888 http://dx.doi.org/10.3390/ph16070976 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Stoeva, Vera Petrova, Guenka Mitov, Konstantin Tachkov, Konstantin Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib |
title | Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib |
title_full | Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib |
title_fullStr | Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib |
title_full_unstemmed | Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib |
title_short | Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib |
title_sort | study of symptom severity and adherence to therapy of myelofibrosis patients treated with ruxolitinib |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383504/ https://www.ncbi.nlm.nih.gov/pubmed/37513888 http://dx.doi.org/10.3390/ph16070976 |
work_keys_str_mv | AT stoevavera studyofsymptomseverityandadherencetotherapyofmyelofibrosispatientstreatedwithruxolitinib AT petrovaguenka studyofsymptomseverityandadherencetotherapyofmyelofibrosispatientstreatedwithruxolitinib AT mitovkonstantin studyofsymptomseverityandadherencetotherapyofmyelofibrosispatientstreatedwithruxolitinib AT tachkovkonstantin studyofsymptomseverityandadherencetotherapyofmyelofibrosispatientstreatedwithruxolitinib |